Scarica l'app Stockscreener
2.44
1.21%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Esperion Therapeutics soars amid vague takeover speculation - MSN
Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio - MSN
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Citizens raises Esperion Therapeutics price target on drug growth By Investing.com - Investing.com Canada
Esperion Therapeutics (ESPR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Equities Analysts Issue Forecasts for ESPR Q1 Earnings - MarketBeat
Esperion Stock Pre-Market (-0.1%): EPS Miss Mutes Revenue Beat & Acquisition News - Trefis
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down - Yahoo Finance
Esperion at Citizens Life Sciences: Strategic Growth and Acquisition - Investing.com
What is HC Wainwright's Estimate for ESPR Q4 Earnings? - MarketBeat
Esperion Therapeutics (ESPR) Turns Q4 Profit As Bears Question Trailing Losses And Balance Sheet - Sahm
Esperion Therapeutics Q4 2025 earnings preview - MSN
ESPR stock falls after Esperion’s mixed Q4 — retail remains unfazed, eyes ‘massive’ upcoming catalysts - MSN
H.C. Wainwright Maintains Buy on Esperion Therapeutics (ESPR) March 2026 - Meyka
Esperion Therapeutics, Inc (ESPR) Misses Q4 EPS Estimates - AlphaStreet
Esperion shares rise 8% after revenue tops forecasts and acquisition announced - MSN
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 5.1%Time to Sell? - MarketBeat
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
Esperion Therapeutics Reports Strong 2025 Revenue Growth, Expands Global Cardiovascular Franchise and Advances New Therapies - Minichart
Esperion Therapeutics, Inc (ESPR) Reports Q4 Earnings - AlphaStreet
Esperion Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Esperion Q4 2025 slides: 38% sales growth, $4.6B CHF opportunity - Investing.com Nigeria
ESPR: Record revenue growth and strategic expansion set the stage for sustained momentum in 2026 - TradingView
Earnings call transcript: Esperion Therapeutics Q4 2025 misses EPS but sees revenue surge - Investing.com Canada
Esperion Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ESPR) 2026-03-10 - Seeking Alpha
Esperion shares jump 8% on revenue beat, acquisition plans - Investing.com
Esperion Therapeutics (NASDAQ:ESPR) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Q4 profit and 21% FY25 revenue growth at Esperion (NASDAQ: ESPR) - Stock Titan
Esperion Q4 2025 Earnings: $61.8M Profit, $168.4M Revenue Exceeds EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates - Yahoo Finance
Esperion Therapeutics Swings to Q4 Earnings, Revenue Rises - marketscreener.com
Earnings Flash (ESPR) Esperion Therapeutics Posts Q4 EPS $0.22, vs. FactSet Est of $0.27 - marketscreener.com
ESPERION THERAPEUTICS ($ESPR) Releases Q4 2025 Earnings - Quiver Quantitative
Esperion Therapeutics: Fourth Quarter Earnings Overview - Bitget
Esperion Therapeutics: Q4 Earnings Snapshot - Barchart.com
Esperion Therapeutics Q4 revenue jumps 144% on US product strength - TradingView
Esperion Reports 21% Revenue Growth in FY25, Announces Strategic Acquisition of Corstasis Therapeutics - Quiver Quantitative
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
BRIEF-Esperion Therapeutics Q4 Product Sales USD 43.723 Million - TradingView
Esperion to acquire first FDA-approved nasal spray diuretic in $4B market - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.2%What's Next? - MarketBeat
United StatesArnold & Porter Advises Corstasis In Sale To Esperion - Mondaq
A Peek at Esperion Therapeutics's Future Earnings - Benzinga
Market Rankings: Can Esperion Therapeutics Inc outperform under higher oil pricesPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Esperion settles litigation with Accord Healthcare - MSN
Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet - RTTNews
/C O R R E C T I O N -- HLS Therapeutics Inc./ - Yahoo Finance
Royce & Associates LP Takes Position in Esperion Therapeutics, Inc. $ESPR - MarketBeat
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - The Globe and Mail
Esperion Therapeutics Hits Day Low of $2.83 Amid Price Pressure - Markets Mojo
electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Finviz
Esperion to acquire Corstasis for cardiovascular franchise expansion - Pharmaceutical Technology
Esperion Therapeutics: $75 Million Acquisition Of Corstasis To Expand Cardiovascular Franchise With Enbumyst Nasal Spray - Pulse 2.0
1.15%
3.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):